Ambys Medicines Announces Formation of Clinical and Scientific Advisory Boards with Leading Liver Disease and Cell and Gene Therapy Experts

Published : Monday, June 27, 2022, 8:00 am
ACROFAN=Business Wire | | SNS

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Ambys Medicines, a company pioneering cell-replacement therapies for patients with liver disease, today announced the formation of its clinical and scientific advisory boards comprising leading clinical experts in liver disease and hepatocyte transplantation, and world-class scientists pioneering cell and gene technologies.

The clinical advisory board provides guidance on advancing Ambys’s lead program, AMI-918, through the clinic and provides critical input on clinical trial design and patient selection. The scientific advisory board will provide a cross-discipline perspective on applying cutting-edge technology to Ambys’s cell therapy platform to progress its discovery pipeline of next generation cell therapies.

“We’re honored to work with such an esteemed and diverse group of experts in liver disease, hepatocyte transplantation, and cell and gene therapies whose collective experience will be highly valuable as we finalize our clinical development strategy for AMI-918 and progress our genetically engineered hepatocyte follow-on programs,” said Ronald Park, M.D., Chief Executive Officer of Ambys Medicines. “We’re grateful for the engagement and support from our advisors as we work to bring first-in-class hepatocyte replacement therapies to liver failure patients who currently lack treatment options.”

“Each of our advisors brings incredible knowledge and expertise in their respective fields that will be instrumental to Ambys as we continue to broaden our pipeline and move closer to becoming a clinical-stage company,” said Markus Grompe, M.D., Founder and Chief Scientific Officer of Ambys Medicines. “We’re excited to partner together to realize the potential of our novel replacement cell therapy platform in restoring lost hepatic function to patients with acute or chronic liver failure and genetic liver diseases.”

Clinical Advisory Board

  • Robert S. Brown Jr., M.D., MPH, Vincent Astor Distinguished Professor of Medicine and Chief, Division of Gastroenterology and Hepatology, Weill Cornell Medicine
  • Raymond Chung, M.D., Vice Chief of Gastroenterology, Director of Hepatology and the Liver Center, and Kevin and Polly Maroni MGH Research Scholar, Massachusetts General Hospital; Professor of Medicine, Harvard Medical School
  • Steven D. Colquhoun, M.D., Professor of Surgery, Surgical Oncology and Hepato-Pancreato-Biliary Surgery, Cedars Sinai Medical Center; Former Director of Liver Transplantation, University of California Davis
  • Robert Fisher, M.D., Medical Director, CTI; Former Chief, Division of Transplantation, Beth Israel Deaconess Medical Center; Professor of Surgery, Harvard Medical School
  • Paul Kwo, M.D., Professor of Medicine and Director of Hepatology, Stanford University
  • Scott Naugler, M.D., Professor of Medicine, Medical Director of Multi-Disciplinary Liver Tumor Clinic and Medical Director of Liver Transplantation, Oregon Health and Science University
  • Stephen Strom, Ph.D., Professor of Cell Transplantation Research, Department of Laboratory Medicine, Karolinska Institutet

Scientific Advisory Board

  • Daniel P. Anderson, Ph.D., Professor, Chemical Engineering and Institute for Medical Engineering and Science, Massachusetts Institute of Technology; Member, Marble Center for Cancer Nanomedicine; Associate Member, Broad Institute of MIT and Harvard; and Associate Member, Ragon Institute at MGH, MIT and Harvard
  • Michael Holmes, Ph.D., Chief Scientific Officer, Tessera Therapeutics
  • Brendan Lee, M.D., Ph.D., Robert and Janice McNair Endowed Chair, Professor and Chairman of the Department of Molecular and Human Genetics; Director of the Center for Skeletal Medicine and Biology, Baylor College of Medicine; and Co-Director of the Texas Medical Center Bone Disease Program of Texas
  • Yury Popov, M.D., Ph.D., Associate Professor of Medicine, Harvard Medical School; Co-Director, Pathogens Immunity and Inflammation Translational Hub and Director, Liver Fibrosis Research, Beth Israel Deaconess Medical Center
  • David Russell, M.D., Ph.D., Professor Emeritus of Medicine and Principal Investigator, Russell Lab, Division of Hematology, School of Medicine, University of Washington
  • Holger Willenbring, M.D., Ph.D., Professor of Surgery and Associate Director, Liver Center, University of California San Francisco; Member, Eli and Edythe Broad Center of Regeneration Medicine and Stem Cell Research

About Ambys Medicines
Ambys Medicines is focused on pioneering cell replacement therapies for patients with liver failure. Ambys’s proprietary platform enables the company to be the first and only company able to develop and manufacture functional human hepatocytes at scale. Our scientific approach has the potential to fundamentally transform the treatment paradigm for patients with acute and chronic liver failure and genetic diseases of the liver. Our lead program, AMI-918, is a hepatocyte replacement cell therapy in development to restore lost hepatic function. Beyond AMI-918, we are building a pipeline of next-generation modified hepatocytes that will rapidly expand the range of treatable patient populations. Learn more at and follow us on Twitter, LinkedIn and Instagram.


Michele Rozen
Scient Public Relations

Copyright © acrofan/Business Wire All Right Reserved

    Acrofan     |     Contact Us :     |     Contents API : RSS

Copyright © Acrofan All Right Reserved